CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to tumor cells. When administered with a ...

The open-label Phase 2 trial enrolled 48 patients in the mITT population with non-resectable locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC) across the ...

Candel Therapeutics, Inc. has reported positive final survival data from a phase 2 clinical trial assessing CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC).

In the Company’s randomized phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic cancer, positive survival data showed notable improvement in estimated median overall survival ...

"PanTher Therapeutics launches second trial for chemotherapy patch" was originally created and published by Medical Device Network, a GlobalData owned brand.

PRESENTATION #E25-2265: NANORAY Pancreas: A Phase 1 Study of NBTXR3 (JNJ-1900) Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC) ...

Prognostic implication of body composition changes in patients with borderline resectable/locally advanced pancreatic adenocarcinoma (PDAC) treated with mFOLFIRINOX. Authors: Jong Hyuk Lee, Hyehyun ...

CAN-2409 - Pancreatic Cancer Positive final survival data from the randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable PDAC demonstrated notable improvement in ...

Source Reference: Reyngold M, et al "Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy" JAMA Oncol 2025; DOI: 10.1001/jamaoncol.2025.0460.

Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...

On January 24, 2008, as part of the 2008 Gastrointestinal Cancers Symposium (Orlando, Florida), a 1-day consensus conference was held on resectable and borderline resectable pancreatic adenocarcinoma.